Skip to content
Sharism- Lifestyle
Author:
Oblenio Bio, Inc.
Oblenio Announces First Patients Dosed in Innovative Phase 1a Trial of LBL-051 in Refractory Autoimmune Diseases
August 4, 2026
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
June 25, 2026